From GE Healthcare;;
Optison is the first 'second generation USCA' marketed in the US.
Ultrasound contrast agents used during an ultrasound imaging procedure, enable more accurate diagnosis of the patient's heart condition. The application of Optison allows to image the endocardial borders of the heart, to see cardiac wall motion abnormalities and to guide the selection and monitoring of treatment.
Optison represents a class of microbubbles with a shell formed by sonicating a solution of capsules filled with a perfluoropropane gas. The high molecular weight slows microbubble dissolution and prolongs the enhancement for several minutes. The human albumin-stabilized cavitation bubbles have a surface tension of 0.9 N/m and a surface dilatational viscosity 0.08 msP.

'August 06, 2001 Molecular Biosystems Inc., a subsidiary of Alliance Pharmaceutical Corp, announced the amendment of the Optison Product Rights Agreement (OPRA) dated May 9, 2000 with Mallinckrodt Inc, a unit of Tyco Healthcare. Optison, an intravenous ultrasound contrast agent, was developed by MBI and is being marketed by Mallinckrodt in the U.S. and Europe. Under the amended agreement, MBI will receive an immediate cash payment plus additional unspecified royalties for a two-year period. The amendment of OPRA coincides with an announcement by Nycomed Amersham Imaging that Nycomed and Mallinckrodt will terminate their joint commercialization and development agreement for ultrasound contrast agents, including Optison, effective Dec. 31, 2001. Effective Jan. 1, 2002, all selling and marketing activities will be resumed solely by Nycomed Amersham.'

The second generation ultrasound contrast agents (UCA/USCA) are both sufficiently small and stable to pass into the systemic circulation, and these contrast media enhance the Doppler signal in various arteries after intravenous injection. Second generation agents have a short live, the contrast effect is over in a few minutes.

From Bracco Diagnostics, Inc.
SonoVue® was first launched in October 2001 and is now available in all European countries.
SonoVue is a second generation USCA, designed and optimized with regard to the resistance to pressure. SonoVue is an example of an important family of microbubbles whose membrane consists of phospholipids. SonoVue microbubbles are filled with sulfur hexafluoride (SF6), a gas which has a low solubility and diffuses slowly in blood for the gaseous phase of the microbubbles.
In particular, the SonoVue microbubbles, thanks to the high flexibility of their shell, are strongly echogenic in a wide range of frequencies and acoustic pressure and therefore can be used with both destructive and conservative contrast bubble specific imaging methods.

See also Coherent Contrast Imaging.

(TCD) Transcranial color Doppler sonography allows to evaluate the presence and flow direction of vessels as well as their relationships to surrounding structures.
A disadvantage of cerebrovascular ultrasonography is the attenuation of the ultrasound signal by the skull. The loss of power through the skull is considerable, the signal to noise ratio is poor and so contrast enhanced Doppler imaging is advantageous. The use of ultrasound contrast agents provides a diagnostic window of sufficient duration and imaging quality to improve an evaluation of the cerebral vessels. Contrast TCD also results in visualization of small arteries and veins and greater length of these vessels.

See also A-Mode, Cranial Bone Thermal Index, Transcranial Color Coded Sonography and Transcranial Window.

(TEE) Transesophageal echocardiography provides a superior view of cardiac anatomy compared with transthoracic echocardiography. TEE is performed by the introduction of a probe attached to a fiberoptic endoscope into the esophagus. Caused by the position close to the heart e.g., clot finding and the view of the mitral valve are improved.

Indications:
The piezoelectric crystal creating the acoustic power is mounted on the gastroscope that must be swallowed by the patient. This endoscopic transducer is miniaturized to approximately the size of a fingernail. Usually the probe is in place for an average of 15 minutes, to numb the surface a topical anesthetic is sprayed into the throat, in addition a conscious sedation is recommended.

See also Myocardial Contrast Echocardiography, Stress Echocardiogram, M-Mode Echocardiography, Contrast Enhanced Ultrasound and Vascular Ultrasound Contrast Agents.